Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024年1月4日 - 10:00PM
Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief
Executive Officer and President, Ram Aiyar, Ph.D., will present at
the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday,
January 9, 2024 at 11:15 a.m. PT (2:15 p.m. ET) in the Borgia Room
at The Westin St. Francis Hotel in San Francisco. Chief Financial
Officer, Vineet Agarwal, and Chief Scientific Officer, Steve
Colletti, Ph.D., will also be participating at the conference.
Dr. Aiyar will present new platform data and
preclinical data on its first development candidate, KRRO-110, for
the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD).
As previously announced, preclinical development of KRRO-110 is
ongoing in preparation for a potential regulatory filing in the
second half of 2024.
A live webcast of the presentation can be
accessed from the Investor section of Korro’s website at
www.korrobio.com. Following the presentation, a replay of the event
will be available for 30 days.
About Korro
Korro is a biopharmaceutical company focused on
developing a new class of genetic medicines for both rare and
highly prevalent diseases using its proprietary RNA editing
platform. Korro is generating a portfolio of differentiated
programs that are designed to harness the body’s natural RNA
editing process to effect a precise yet transient single base edit.
By editing RNA instead of DNA, Korro is expanding the reach of
genetic medicines by delivering additional precision and
tunability, which has the potential for increased specificity and
improved long-term tolerability. Using an oligonucleotide-based
approach, Korro expects to bring its medicines to patients by
leveraging its proprietary platform with precedented delivery
modalities, manufacturing know-how, and established regulatory
pathways of approved oligonucleotide drugs. Korro is based in
Cambridge, Mass. For more information, visit
korrobio.com.
Forward-Looking Statements
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995, including express or implied statements regarding the timing
of Korro’s regulatory filings for KRRO-110, Korro’s ability to
replicate results from preclinical studies in clinical trials,
KRRO-110’s ability to restore production of normal A1AT and its
potential as a game-changing therapeutic, as well as Korro’s
ability to move additional candidates into the clinic and expand
the reach of genetic medicines, among others. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as “may,” “will,” “should,” “would,” “expect,”
“anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,”
“intend,” and other similar expressions among others. Statements
that are not historical facts are forward-looking statements.
Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not
guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: risks
related to (i) biopharmaceutical development generally; (ii)
conducting preclinical studies and clinical trials, including
obtaining necessary regulatory approvals; (iii) protecting and
enforcing intellectual property; (iv) integrating operations
post-merger and operating the combined company as a public company
as well as other risks related to the recent business combination;
(v) legislative, regulatory and economic developments; (vi)
unpredictability and severity of catastrophic events, including,
but not limited to, acts of terrorism or outbreak of war or
hostilities, such as the recent Hamas-Israeli conflict, as well as
management’s response to any of the aforementioned factors; and
(vii) such other factors as are set forth in Exhibit 99.2 to the
Current Report on Form 8-K filed with the SEC on November 6, 2023
as may be supplemented or amended by other SEC filings. Except as
required by applicable law, Korro undertakes no obligation to
revise or update any forward-looking statement, or to make any
other forward-looking statements, whether as a result of new
information, future events or otherwise.
Korro Contact
Information Investors IR@korrobio.com
Media Glenn Silver FINN
Partners Glenn.silver@finnpartners.com
Korro Bio (NASDAQ:KRRO)
過去 株価チャート
から 4 2024 まで 5 2024
Korro Bio (NASDAQ:KRRO)
過去 株価チャート
から 5 2023 まで 5 2024